Investigate the Safety, Tolerability and Pharmacokinetics of CHF6523 in Healthy and in COPD Subjects

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
This study is designed to investigate the safety, tolerability and pharmacokinetics of inhaled CHF6523 DPI in healthy male subjects first and then in COPD subjects after single or repeated dosesof CHF6523. As an exploratory assessment, the anti‐inflammatory effect of CHF6523 in COPDsubjects will be evaluated.
Epistemonikos ID: 679cd568ae1f7b7e788b6658fc905850481a6374
First added on: May 22, 2024